Unlock instant, AI-driven research and patent intelligence for your innovation.

Quinazoline compounds

A compound, optionally a technology, applied in the direction of active ingredients of heterocyclic compounds, drug combinations, organic chemistry, etc., can solve the problems of inflammation and inhibition of pro-inflammatory gene expression, etc.

Inactive Publication Date: 2010-03-24
WYETH LLC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In addition to the lipid and triglyceride effects described above, LXR activation is also thought to lead to inflammation and suppression of pro-inflammatory gene expression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinazoline compounds
  • Quinazoline compounds
  • Quinazoline compounds

Examples

Experimental program
Comparison scheme
Effect test

example

[0709] The preparation of representative compounds of the invention is illustrated below. Compounds described as homogeneous were determined to have a purity of 90% or greater (excluding enantiomers) by analytical reverse phase chromatography using 254 nM UV detection. Melting points are reported in uncorrected degrees Celsius. Mass spectral data are reported as mass-to-charge ratio m / z; and for high-resolution mass spectral data, calculated and experimentally measured masses [M+H] for neutral formula M + Report. All reactions were stirred and performed under nitrogen atmosphere unless otherwise stated.

example 1

[0711] 4-(3-Methoxyphenyl)-8-(trifluoromethyl)quinazoline

[0712] A stirred mixture of (2-amino-3-(trifluoromethyl)phenyl)(3-methoxyphenyl)methanone (2.95 g, 10.0 mmol), formic acid (5 mL) and formamide (20 mL) Heated at 150 °C for 4 h under a nitrogen atmosphere. After 1 h, the reaction was cooled, poured into ice water (150 mL), and extracted with dichloromethane (2 x 50 mL). The combined extracts were dried (MgSO 4 ) and concentrated in vacuo. Chromatography on silica gel (gradient 15 / 85 to 30 / 70 E / H) afforded the title compound (1.04 g, R in 35 / 65 E / H) as a white solid. f approximately equal to 0.5). MS (ES) m / z 304.6; HRMS: C 16 h 11 f 3 N 2 O+H + The calculated value of is 305.08962; the experimental value (ESI, [M+H] + ) is 305.0896.

example 2

[0714] 3-(8-(trifluoromethyl)quinazolin-4-yl)phenol

[0715] A stirred mixture of 4-(3-methoxyphenyl)-8-(trifluoromethyl)quinazoline (915mg, 3.00mmol) and pyridine hydrochloride (6.5g) was heated at 200-205°C in Heated under nitrogen atmosphere. After 2.5 h, the reaction was poured into water (50 mL), washed with saturated NaHCO 3 The aqueous solution (100 mL) was treated and extracted with dichloromethane (100 mL). The combined extracts were dried (MgSO 4 ) and concentrated in vacuo. Chromatography on silica gel (30 / 70 to 60 / 40E / H gradient) afforded the title compound (810 mg, R in 50 / 50E / H) as a white solid. f approximately equal to 0.3). MS (ES) m / z 290.9.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates generally to quinazoline-based modulators of Liver X receptors (LXRs) and related methods.

Description

[0001] Related Application Cross Reference [0002] This application claims the benefit of US Provisional Application Serial No. 60 / 938,801, filed May 18, 2007, which is hereby incorporated by reference in its entirety. technical field [0003] In general, the present invention relates to quinazoline-based liver X receptor (LXR) modulators and related methods. Background technique [0004] Atherosclerosis is one of the leading causes of death in developed countries. Some independent risk factors associated with atherosclerosis include the presence of relatively high levels of serum LDL cholesterol and relatively low levels of serum HDL cholesterol in affected patients. Accordingly, some anti-atherosclerotic therapy regimens involve the administration of agents (eg, statins) that reduce elevated serum LDL cholesterol levels. [0005] Agents that increase HDL cholesterol levels in a patient may also be used in anti-atherosclerotic regimens. HDL cholesterol is thought to pl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/74A61K31/33A61P29/00
CPCC07D239/74A61P1/04A61P1/16A61P17/00A61P17/16A61P17/18A61P19/02A61P19/04A61P19/08A61P25/28A61P29/00A61P3/04A61P31/04A61P3/06A61P43/00A61P9/00A61P9/10A61P3/10
Inventor 罗纳德·查尔斯·别尔诺塔斯约翰·威廉·乌尔里克杰里米·马克·特拉温斯杰伊·E·弗罗贝尔拉约曼德·J·昂瓦拉
Owner WYETH LLC